SunGlowInnovations

Evidence summary

The investigator brochure summarizes 22 animals with spontaneous tumors: 19 dogs and 3 cats. Clinical signs and local tissue changes varied by case.

Which animals were included

Veterinary records covered spontaneous tumors in 19 dogs and three cats. Sites included the mouth, tongue, nasal cavity, mammary tissue and other locations. The series also included multicentric lymphoma. Records covered immediate observations, changes in local tissue, symptoms and follow-up.

Immediate and follow-up observations

For directly visible lesions, some cases showed a distinct change in vascular appearance within about 15–20 minutes. The records also describe instances of local bleeding stopping and of dead tissue separating later. The brochure records similar immediate local responses in animals that had repeat sessions.

Follow-up in one cat

A day-8 photograph in one feline case showed a dark scab in one region and a red area in another. By day 20, the documented regrowth was in the area with incomplete initial coverage. The brochure uses this example to show why it tracks delivery coverage separately from later changes in tissue.

Events recorded during follow-up

The records include local infection, fever and skin ulceration. One animal with pre-existing lung and liver metastases and heart disease died on day 11. The brochure records the cause of death as undetermined.

Companion animal case records

The table covers the 22 animals in the intratumoral series in IND Module 2.5, Table 6-1, with a data cutoff of October 22, 2026. Each row pairs the recorded local response with safety observations and follow-up.

Scroll sideways to read all columns.

CaseSpecies and tumorLocal responseSafety recordFollow-up
P0 Dog · Shoulder tumorThe lesion collapsed with dry necrosis.No infection recorded.Healed by day 30.
P1 Cat · Subcutaneous mammary tumorThe lesion separated along a clearly defined plane.No adverse event recorded.Separated on day 7, re-epithelialized on day 20 and healed by day 40.
P2 Dog · Mammary adenocarcinoma, three massesThe three masses developed necrosis on days 3–6.No systemic toxicity recorded during follow-up.Documented through day 6.
P4 Dog · Oral sarcoma of the mandibleThe record estimates 50%–75% shrinkage by day 7 and describes marked necrosis in the residual area after repeat treatment.No adverse event recorded.Appetite and activity improved in the record.
P5 Dog · Oral malignant melanomaThe mass was estimated at about half its original size on day 3, with viable tissue in an area of incomplete coverage.Death on day 11 in an animal with lung and liver metastases and cardiac disease. No necropsy was performed and the cause was undetermined.Extensive necrosis and collapse on day 10.
P6 Dog · Soft tissue sarcomaCT showed several well-defined distribution zones. The mass later collapsed markedly.Ulceration of the overlying skin.No swelling or bleeding on day 1. Marked collapse on day 10.
P7 Dog · Chest-wall sarcomaThe contour changed without measurable shrinkage in the record.Overlying skin remained intact.Contour assessed on day 12.
P8 Dog · Tumor of the tongue and tongue baseExtensive necrosis was documented on day 2. The tongue and most of the tumor separated on day 4.Tongue loss had been documented as anticipated before treatment. Tube feeding was used.Most of the tumor bulk was gone after the second session, with small residual areas noted.
P9 Dog · Recurrent oral melanomaEstimated volume fell from about 28 mL to 15 mL with necrotic cavities.No adverse event recorded.An immediate color change was documented at the second session on day 18.
P10 Cat · Forelimb squamous cell carcinomaBleeding stopped and a dry black scab formed in the treated region.No adverse event recorded.By day 20, regrowth was recorded only in the area of incomplete initial coverage.
P11 Cat · Deep nasal tumorCT-guided administration was completed.No adverse event reported in the case table.Follow-up was ongoing at the data cutoff.
P12 Dog · Bilateral nasal tumorCT documented distribution and an uncovered area.Dark red nasal discharge the next day.Walking was documented during recovery, followed by next-day observations.
P13 Dog · Recurrent mandibular sarcomaMost of the exposed surface darkened. Viable areas remained where coverage was incomplete.No adverse event recorded.Surface appearance documented at about 24 hours.
P14 Dog · Bleeding oral tumorNecrotic change was visible at about 15 minutes and bleeding stopped.No adverse event recorded.The case table records cancellation of the planned debulking and immediate observation.
P15 Dog · Oral malignant tumorThe mass was estimated to shrink by about two-thirds at 30 hours. Normal eating was reported.Fever and necrotic discharge on day 2 resolved after management.Three sessions over about one month. The site was nearly flush with the mucosa at the third session.
P16 Dog · Recurrent hindlimb tumorMost of the tumor sloughed by day 8.Edema and infection under the scab were recorded. The infection required debridement.No visible residual after scab removal on day 21.
P17 Dog · Vaginal and mammary tumorsThe vaginal tumor surface dried and turned gray-yellow, with loss of visible vascular appearance.No adverse event recorded in the case table.The record primarily covers observations during delivery.
P18 Dog · Prostate tumorDirect observation documented persistent yellow discoloration. Hematuria stopped by day 6.No adverse event recorded. All 15 reported chemistry values were within reference range on day 18.Estimated volume decreased by about 42% by day 18.
P19 Dog · Three adjacent mammary tumorsOn day 2, the visible contact zone was smaller than the main tumor. The main tumor separated as a whole on day 9. The other two lesions also separated.No infection recorded.Healed in about three weeks.
P-MS Dog · Multiple mammary tumorsUltrasound documented visible delivery distribution in multiple lesions.No adverse event reported.The table primarily records imaging and observations at delivery.
P20 Dog · Multicentric lymphomaUltrasound-guided delivery was completed in multiple larger masses.Normal recovery and no abnormalities recorded through day 16.Clinical observation through day 16.
P21 Dog · Nasal mast cell tumor with adenomaPost-treatment CT documented coverage of most of the tumor and some leakage.Normal recovery recorded with no other adverse event in the case table.Around day 10, the owner reported dark granular material expelled by sneezing. Follow-up CT was planned.